Cargando…
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974838/ https://www.ncbi.nlm.nih.gov/pubmed/17465997 http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x |
_version_ | 1782135051418337280 |
---|---|
author | Mercado, Moises Borges, Fatima Bouterfa, Hakim Chang, Tien-Chun Chervin, Alberto Farrall, Andrew J Patocs, Attila Petersenn, Stephan Podoba, Jan Safari, Mitra Wardlaw, Joanna |
author_facet | Mercado, Moises Borges, Fatima Bouterfa, Hakim Chang, Tien-Chun Chervin, Alberto Farrall, Andrew J Patocs, Attila Petersenn, Stephan Podoba, Jan Safari, Mitra Wardlaw, Joanna |
author_sort | Mercado, Moises |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and constituted the population used for this analysis. MEASUREMENTS AND RESULTS: A clinically relevant reduction (i.e. to ≤ 5 µg/l) in mean GH (mGH) was recorded in 72% of patients after 24 weeks of treatment, and 42% reached a ‘safe’ GH value (≤ 2·5 µg/l). At week 48, 16 more patients were considered partial GH responders (GH > 2·5 µg/l and ≤ 5 µg/l) and 44% had reached a GH level ≤ 2·5 µg/l. IGF-1 levels normalized in 38% and 34% of patients after 24 and 48 weeks of treatment, respectively. At study completion, 10 patients (14·7%) who had not normalized their IGF-1 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298 ± 145 mm(3) to 139 ± 94 mm(3) after 24 weeks and to 99 ± 70 mm(3) after 48 weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885 ± 5077 mm(3) at baseline and 2723 ± 3435 and 2406 ± 3207 mm(3) after 24 and 48 weeks, respectively. At weeks 24 and 48, a significant (> 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period. CONCLUSION: Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease. |
format | Text |
id | pubmed-1974838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-19748382007-09-10 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly Mercado, Moises Borges, Fatima Bouterfa, Hakim Chang, Tien-Chun Chervin, Alberto Farrall, Andrew J Patocs, Attila Petersenn, Stephan Podoba, Jan Safari, Mitra Wardlaw, Joanna Clin Endocrinol (Oxf) Original Articles OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and constituted the population used for this analysis. MEASUREMENTS AND RESULTS: A clinically relevant reduction (i.e. to ≤ 5 µg/l) in mean GH (mGH) was recorded in 72% of patients after 24 weeks of treatment, and 42% reached a ‘safe’ GH value (≤ 2·5 µg/l). At week 48, 16 more patients were considered partial GH responders (GH > 2·5 µg/l and ≤ 5 µg/l) and 44% had reached a GH level ≤ 2·5 µg/l. IGF-1 levels normalized in 38% and 34% of patients after 24 and 48 weeks of treatment, respectively. At study completion, 10 patients (14·7%) who had not normalized their IGF-1 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298 ± 145 mm(3) to 139 ± 94 mm(3) after 24 weeks and to 99 ± 70 mm(3) after 48 weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885 ± 5077 mm(3) at baseline and 2723 ± 3435 and 2406 ± 3207 mm(3) after 24 and 48 weeks, respectively. At weeks 24 and 48, a significant (> 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period. CONCLUSION: Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease. Blackwell Publishing Ltd 2007-06-01 /pmc/articles/PMC1974838/ /pubmed/17465997 http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x Text en © 2007 The Authors Journal compilation © 2007 Blackwell Publishing Ltd https://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2·5, which does not permit commercial exploitation. |
spellingShingle | Original Articles Mercado, Moises Borges, Fatima Bouterfa, Hakim Chang, Tien-Chun Chervin, Alberto Farrall, Andrew J Patocs, Attila Petersenn, Stephan Podoba, Jan Safari, Mitra Wardlaw, Joanna A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title | A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title_full | A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title_fullStr | A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title_full_unstemmed | A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title_short | A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
title_sort | prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide lar® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974838/ https://www.ncbi.nlm.nih.gov/pubmed/17465997 http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x |
work_keys_str_mv | AT mercadomoises aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT borgesfatima aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT bouterfahakim aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT changtienchun aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT chervinalberto aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT farrallandrewj aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT patocsattila aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT petersennstephan aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT podobajan aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT safarimitra aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT wardlawjoanna aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT mercadomoises prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT borgesfatima prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT bouterfahakim prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT changtienchun prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT chervinalberto prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT farrallandrewj prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT patocsattila prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT petersennstephan prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT podobajan prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT safarimitra prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly AT wardlawjoanna prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly |